News

Posted: 2013-06-11

Toronto, ON PCC– June 11, 2013 – Prostate Cancer Canada (PCC) is proud to announce the recipients of the inauguralMovember Team Grants.

Posted: 2013-06-10

The VGH and UBC Hospital Foundation's 2013 Mr. Lube Tournament for Life raised a record $370,000 to support care, research and education at the Vancouver Prostate Centre.  Thank you to our sponsors, golfers, guests, donors and volunteers for making this event such a success.  Further information is at the Foundation's website.

Posted: 2013-05-21

Dr. Martin Gleave, BC Leadership Chair in Prostate Cancer Research, UBC Distinguished Professor and Executive Director of the Vancouver Prostate Centre, is the 2013 recipient of the Barringer Medal from the American Association of Genitourinary Surgeons (AAGUS).

This award is presented by the AAGUS to an individual who is doing outstanding work in the field of GU cancer surgery. Dr. Gleave is the first Canadian to be honoured by this award since its inception in 1955.

Posted: 2013-03-20

Prostate Cancer Canada (PCC) has established ‘A Survivorship Action Partnership’ (ASAP) to help improve the lives of prostate cancer survivors and their partners, caregivers and family members across Canada.

The network, led by PCC and funded by Movember, met on Feb. 26 and 27 in Vancouver to share ideas and experience, and focus on the business of providing the right support and education to help everyone touched by the diagnosis of prostate cancer and the decisions, actions and outcomes that follow.

Posted: 2013-02-13

Dr. Martin Gleave, BC Leadership Chair in Prostate Cancer Research, UBC Distinguished Professor and Executive Director of the Vancouver Prostate Centre, is the 2013 recipient of the Eugene Fuller Triennial Prostate Award from the American Urological Association.

Posted: 2013-02-05

The Vancouver Prostate Centre's PC-TRiADD program has recieved an additional award of $11.3 million for 2013 - 2018.

Please read our press release here (PDF) .  A link to the Centres of Excellence for Commercialization and Research story is here.

Posted: 2013-01-28

Toronto, ON – January 28, 2013 – Prostate Cancer Canada (PCC) is proud to announce the recipients of the Rising Star in Prostate Cancer Research program. In its inaugural year, the Movember-funded Rising Star program provides funding to four outstanding scientists to support careers as independent investigators researching prostate cancer.

Posted: 2013-01-21

The breakthrough collaborative work being done by Drs. Colin Collins and Yuzhuo Wang of the Vancouver Prostate Centre is featured in a three-page article in the latest issue of "International Innovation" magazine. 

Click here to view the whole article as a PDF.

Posted: 2012-11-05

Movember, the month-long fundraiser for men's health, has begun.  The funds raised in Canada support men's health issues, specifically prostate cancer and male mental health initiatives. The funds raised are directed to programs run directly by Movember and their men’s health partner, Prostate Cancer Canada.

Posted: 2012-10-11

Many men survive prostate cancer, but thousands of others — whose cancer spreads — inevitably develop resistance to even the most promising treatments, leaving them with few medical options and a dwindling span of life.

Now, armed with a new $10 million grant, a multi-centre “dream team’’ of scientists is embarking on a groundbreaking undertaking into personalized medicine. The goal: to overcome therapeutic resistance in the disease and revolutionize treatment for patients with advanced prostate cancer.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Employment

Work at the Vancouver Prostate Centre

Thursday, January 18, 2018

Discovery of a promising new medication to block "master key" of cancer growth

Dr. Chris Ong
Tuesday, February 20, 2018

Drs. Wyatt and Chi: ctDNA predicts resistance to AR-targeted therapy

VCHRI News article on study of ctDNA predicting resistance to AR-targeted therapy
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.